RECORDATI ANNOUNCES REVENUES UP 8.9% IN THE FIRST HALF 2009

MILAN, ITALY, Jul 14 (MARKET WIRE) --
Recordati announces that its group revenues for the first half 2009 are
EUR 379.3 million, an increase of 8.9% over the same period of the
preceding year. Pharmaceutical sales grow by 10.1% while pharmaceutical
chemicals sales are down. Revenue growth is due mainly to the
international business which increases by 12.5%. In Italy sales are up by
1.2%.

"We are very pleased with the sales achieved in the first half of the
year" declares Giovanni Recordati, Chairman and CEO. "These results are
evidence of the validity of our strategy to grow our pharmaceutical
operations, mainly through the enhancement of our product portfolio and
the expansion of our direct presence in the European pharmaceutical
markets".

Recordati, established in 1926, is a European pharmaceutical group, listed
on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT
0003828271),with a total staff of over 2,900, dedicated to the research,
development, manufacturing and marketing of pharmaceuticals. It has
headquarters in Milan, Italy, operations in the main European countries,
and a growing presence in the new markets of Central and Eastern Europe. A
European field force of over 1,400 medical representatives promotes a wide
range of innovative pharmaceuticals, both proprietary and under license,
in a number of therapeutic areas including a specialized business
dedicated to treatments for rare diseases. Recordati's current and
growing coverage of the European pharmaceutical market makes it a partner
of choice for new product licenses from companies which do not have
European marketing organizations. Recordati is committed to the research
and development of new drug entities within the cardiovascular and
urogenital therapeutic areas and of treatments for rare diseases.
Consolidated revenue for 2008 was EUR 689.6 million, operating income was
EUR 144.7 million and net income was EUR 100.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations Media Relations

Marianne Tatschke Claudio Rossetti (Echo Comunicazione d'Impresa)

(39)0248787393 (39)02 62694736

e-mail: inver@recordati.it e-mail: crossetti@echocom.it

Statements contained in this release, other than historical facts, are
"forward-looking statements" (as such term is defined in the Private
Securities Litigation Reform Act of 1995). These statements are based on
currently available information, on current best estimates, and on
assumptions believed to be reasonable. This information, these estimates
and assumptions may prove to be incomplete or erroneous, and involve
numerous risks and uncertainties, beyond the Company's control. Hence,
actual results may differ materially from those expressed or implied by
such forward-looking statements. All mentions and descriptions of
Recordati products are intended solely as information on the general
nature of the company's activities and are not intended to indicate the
advisability of administering any product in any particular instance.

This information is provided by HUGIN

Copyright 2009, Market Wire, All rights reserved.

-0-